Doing due diligence on the major shareholders and officers of Know Labs
Analyzing Ownership Shares Outstanding 17,531,522
Ownership breakdown Directors and Officers
Ronald P. Erickson 7,889,015 32.6 % Philip A Bosua 2,917,500 16.6 Jon Pepper 238,000 1.4 Ichiro Takesako 150,000 .9 William A Owens 650,000 3.7 _______ ____ 11,844,515 67.6
Clayton Struve 800,000 4.6
Public 4,887,007 27.8% _______ ____ Total 17,531,522 100.00
Fully Diluted Shares Outstanding 49,121,923
Shares Outstanding 17,531,522
Warrants Outstanding 15,473,398 at average price of $ .326
Employee Stock options 2,182,668 at average price of $ 1.70
Convertible Preferred Stock 4,914,071
Convertible Note Payable 9,020,264 at $ .25 share
Grand Total Fully Diluted Shares 49,121,923
Break Down of major shareholders
Clayton A Struve 16,763,790 34% Ronald P Erickson 7,889,015 16% Philip A Bosua 2,917,500 6% Dale Broadrick 2,226,036 4.5%
Total 29,796,341 61%
1) Backgrounds of major shareholders of Know Labs, Inc.-note experience of holders—Note successes
Mr. Clayton A. Struve, Clay has been Partner of CSS LLC, a Proprietary Trading Firm since September 1998. From October 1997 to joining CSS LLC, Mr. Struve pursued personal investment activities.
From January 1991 to October 1997, Mr. Struve served as Managing Director of Swiss Bank Corporation, holding various positions, including co-head of equities and co-head of Global Risk Control.
From 1981 to 1991, Mr. Struve served as Partner at O'Connor & Associates and served Head Of Equities, Head Of Risk and Head of New Products. He also directed development of risk modeling and systems. He has been Director of Peak6 Investment, LP (Alternate name: Peak6 Corp.), since March 2001. Mr. Struve also serves as a Member of the board of directors of O'Connor Partnerships, a Private Investment Firm.
He serves on the boards of Target Discovery Inc., a Biotechnology Firm, and Prediction Cos. LLC, a Quantitative Trading Advisory Firm. Mr. Struve holds a BS in Management and Finance from Massachusetts Institute of Technology.
Ron Erickson (born December 24, 1943, Tacoma, Washington) is an American business executive, lawyer, and angel investor based in Seattle. After co-founding Microrim in 1981,[2] he has either founded or served as an executive for companies such as GlobalTel Resources, Inc.,[2] GlobalVision, Inc,[1][3] Egghead Software, Inc.,[2] and Blue Frog Media. He was the sole investor in Double Down Interactive, a social video game studio[4] that was sold for up to $500 million in 2012.
Early in his career Erickson worked in public policy at the White House and the Office of Economic Opportunity in Washington, D.C.,[7] becoming the latter's Branch Chief for Emergency Food and Medical Services.[1] He also worked for the Rockefeller Commission on Critical Choices in New York City.[7]
He studied law at the University of California at Davis, graduating with a Juris Doctor,[ and is licensed to practice law through the Washington State Bar Association.He has worked in Seattle at firms such as Kargianis, Austin & Erickson, and Ronald P. Erickson & Associates.
Philip Bosua –approximately 45 years old
Company CEO 4/10/18 Chief product officer since 7/7/17 From 9/12 to 2/15 CEO of LIFX, Inc--still owns 9%
“Back in 2012, when a smart home was just whispers and dreams, we kickstarted into action and launched the first ever multicolored LED Wi-Fi light. Its been a crazy 5 years and we now offer 12 products in over 80 countries that bring the future of lighting within your control. Oh, and we’ve made some friends along the way. Like any good smart home product, LIFX works seamlessly with other industry leaders such as Amazon Alexa, Nest & Google Home. You can check out the full range here.”
“Leaders in Wi-Fi connected smart lights.”
“The San Francisco– and Melbourne-based startup launched in 2012 with a $1.3 million Kickstarter crowdfunding raise. It was founded by CEO Phil Bosua, CTO Marc Alexander, Guy King, Jake Lawton, CIO Daniel May and Bevan Clark.”
2) Chief Medical Officer
James Anderson, MD, has joined the Company as Medical Director in September 2018
James H. Anderson, Jr., M.D., FFPM, FACE, is a diabetologist and endocrinologist.
Dr. Anderson previously joined Eli Lilly and Company (LLY) where he was responsible for Lilly’s global clinical diabetes development program. He managed diabetes and cardiometabolic drug clinical development, and drove the clinical development of three families of billion dollar diabetes care products.
Market Data 
Markets 
AI
